Post-earnings recap
Reported
Thu, May 7, 2026
EPS actual
$-1.18
EPS est.
$-1.10
EPS surprise
-6.88%
1-day move
-3.11%
Celldex Therapeutics reported a larger-than-expected loss per share, which contributed to a decline in stock price by 3.11%. The company did not provide revenue figures, leading to uncertainty about its financial performance. Investors may be cautious moving forward due to the lack of guidance and the earnings miss.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.18 | $-1.13 | -6.88% |
| Revenue | $— | $1M | — |
No transcript is on record, and the analysis is based on numerical results only.
Celldex Therapeutics, Inc. (CLDX) is a biotechnology company focused on developing innovative therapies for cancer and other serious diseases. With a market cap of $3 billion, its work in the health care sector is crucial as it aims to address unmet medical needs through advanced treatments.
Last quarter
In Q4 2025, Celldex reported an EPS of $-1.22, missing estimates by 22.37%. The stock reacted positively, gaining over 24% the following day.
EPS beat streak
1Q
EPS beat rate
50%
Avg EPS surprise
-3.61%
Avg 1-day reaction
+3.80%
Analysts expect Celldex to report a loss in EPS and modest revenue, reflecting ongoing challenges in the biotechnology sector. The market will be closely watching for any signs of progress in its drug development pipeline.
Bull case
If Celldex can exceed revenue expectations and show signs of advancing its clinical trials, it could lead to a positive reassessment of its growth potential.
Bear case
Conversely, if the company reports a larger loss than expected or delays in its drug development, it could raise concerns about its financial stability and future prospects.
Key metrics to watch
EPS
$-1.13Earnings per share (EPS) indicates the company's profitability and is a key measure for investors to assess financial health.
Revenue
$1MRevenue figures provide insight into the company's sales performance and market demand for its products.
The print will turn on these.
Q1
Will the EPS come in better than the consensus estimate of $-1.13?
A better-than-expected EPS could indicate improved operational efficiency and investor confidence.
Q2
What are the updates on the company's drug pipeline and expected revenue of $1M?
Insights into the pipeline can significantly impact future revenue projections and investor sentiment.
Est. EPS
$3.70
Est. Rev
$3.9B
Impl. Move
±4.7%
Why consensus could be wrong
The consensus may underestimate Celldex's potential for revenue growth, given recent advancements in its drug pipeline that have not been fully factored in.
Supporting evidence
The company has a history of beating EPS estimates 63% of the time, suggesting potential for a positive surprise.
Options pricing indicates a significant move is expected, which may reflect underlying optimism not captured in consensus estimates.
Key risk
If the company can demonstrate progress in its clinical trials, it could invalidate the current bearish sentiment.
Pre-commit to what would confirm each case.
This quarter's performance is critical as it reflects the company's ability to manage costs and advance its product pipeline amidst a challenging market.
Bull confirmed if
Reporting an EPS loss narrower than $-1.13 and revenue exceeding $1M would support a bullish outlook.
Bear confirmed if
An EPS loss greater than $-1.32 and revenue below $1M would confirm bearish sentiment.
What the market is pricing for the move.
Implied Move
±5.07%
Historical Avg
±5.5%
The options market is pricing in a move of about 5% in either direction, indicating uncertainty around the earnings report.
Options are pricing ±5.1% while CLDX has averaged ±5.5% over the last 8 prints — setup is roughly in line with history.
ATM IV
0.6%
30d HV
40.2%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Celldex beats expectations, history suggests the stock could rise by about 1.18%, confirming a positive outlook.
In line / cautious
If results are in line with expectations, the stock may see muted movement as investors await further clarity on future guidance.
Miss
A miss could lead to a decline of around 8.77%, reflecting investor disappointment and concerns about the company's direction.
The lines on the call that would change the story.